Dear EURETINA Members, A very warm welcome to the July 10th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »July 10th. 2024 “EURETINA-Brief”© Issue No. 295
Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has provided an update following recent regulatory discussions with the U.S. Food and Drug Administration (“FDA”)… Read More »Nanoscope Therapeutics Inc., provides a commercial update on MCO-010 treatment of retinitis pigmentosa (RP) using optogenetic therapy.
Researchers for the Foundation Fighting Blindness (FFB) Clinical Consortium Investigator Group, based in Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan,… Read More »USH2A: self-reported functional vision measured in associated retinal degeneration by the Michigan Retinal Degeneration Questionnaire (MRDQ).
Researchers based at the Department of Biomedical Engineering, University of Houston, Texas and the Department of Ophthalmology, Duke University Medical Centre, Durham, North Carolina, have… Read More »Maintaining proper RHO:PRPH2 ratios in photoreceptors may provide a potential therapeutic approach for intervention.
Dear EURETINA Members, A very warm welcome to the June 27th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »June 27th, 2024 “EURETINA-Brief”© Issue No. 294
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the completion in the first cohort for a Phase… Read More »Opus Genetics Inc., has announced completion of dowsing in first cohort Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.
A new real-world study, led by Massachusetts General Hospital, Harvard Medical School, Boston, US, have reported a major adverse event on hydroxychloroquine retinopathy, with an… Read More »Hydroxychloroquine dose and duration of use are associated with the risk of hydroxychloroquine retinopathy in a US study.
Researchers based at the MRC Human Genetics Unit, at the University of Edinburgh, and the Western General Hospital (Edinburgh), have reported a new study indicating… Read More »X-linked retinitis pigmentosa (XLRP) due to RPGR variants report new data on actin dynamics.
Dear EURETINA Members, A very warm welcome to the June 10th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »June 10th, 2024 “EURETINA-Brief”© Issue No. 293
A consortium of researchers across Australia, New Zealand, USA, Italy, Portugal, Singapore, Netherlands, Taiwan and Canada, have reported a new study evaluating clinical, electrophysiological and… Read More »Variants in peripherin 2 (PRPH2 gene) shows genetic, functional and clinical observations on 241 IRD patients.
